Next 10 |
home / stock / cadl / cadl articles
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wedn...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for ...
The U.S. stock market experienced a downturn on Thursday, with the Dow Jones index falling by 1.35% to 38,596.98. The NASDAQ and the S&P 500 al...
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.5...
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-qua...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39...
Thursday, Candel Therapeutics Inc (NASDAQ:CADL) released updated interim survival data from the ongoing phase 2 trial of CAN-2409 plus va...
Thursday, Candel Therapeutics Inc (NASDAQ:CADL) announced the presentation of updated data from an ongoing phase 1b trial of its herpes s...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
2024-05-16 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wedn...
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024 On track for top...